[go: up one dir, main page]

HUP0400371A3 - Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation - Google Patents

Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation

Info

Publication number
HUP0400371A3
HUP0400371A3 HU0400371A HUP0400371A HUP0400371A3 HU P0400371 A3 HUP0400371 A3 HU P0400371A3 HU 0400371 A HU0400371 A HU 0400371A HU P0400371 A HUP0400371 A HU P0400371A HU P0400371 A3 HUP0400371 A3 HU P0400371A3
Authority
HU
Hungary
Prior art keywords
preparation
function
pharmaceutical composition
carbon monoxide
following transplantation
Prior art date
Application number
HU0400371A
Other languages
English (en)
Original Assignee
Beth Israel Hospital
Univ Yale
Ikaria Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0400371(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beth Israel Hospital, Univ Yale, Ikaria Holdings filed Critical Beth Israel Hospital
Publication of HUP0400371A2 publication Critical patent/HUP0400371A2/hu
Publication of HUP0400371A3 publication Critical patent/HUP0400371A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400371A 2001-06-21 2002-06-21 Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation HUP0400371A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30028901P 2001-06-21 2001-06-21
US33434001P 2001-11-29 2001-11-29
US33797401P 2001-12-07 2001-12-07
PCT/US2002/019687 WO2003000114A2 (en) 2001-06-21 2002-06-21 Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis

Publications (2)

Publication Number Publication Date
HUP0400371A2 HUP0400371A2 (hu) 2004-08-30
HUP0400371A3 true HUP0400371A3 (en) 2010-06-28

Family

ID=27404726

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400371A HUP0400371A3 (en) 2001-06-21 2002-06-21 Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation

Country Status (25)

Country Link
US (2) US7238469B2 (hu)
EP (2) EP2033514A3 (hu)
JP (1) JP4521183B2 (hu)
KR (1) KR20040032115A (hu)
CN (1) CN100502650C (hu)
AT (1) ATE413883T1 (hu)
AU (2) AU2002318377B2 (hu)
BG (1) BG108492A (hu)
BR (1) BR0210599A (hu)
CA (1) CA2451266A1 (hu)
CY (1) CY1108798T1 (hu)
CZ (1) CZ20033448A3 (hu)
DE (1) DE60229848D1 (hu)
DK (1) DK1404811T3 (hu)
ES (1) ES2316583T3 (hu)
HU (1) HUP0400371A3 (hu)
MX (1) MXPA03012031A (hu)
NO (1) NO20035637L (hu)
NZ (1) NZ562962A (hu)
PL (1) PL367544A1 (hu)
PT (1) PT1404811E (hu)
SG (1) SG147305A1 (hu)
SI (1) SI1404811T1 (hu)
SK (1) SK15942003A3 (hu)
WO (1) WO2003000114A2 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2033514A3 (en) 2001-06-21 2009-04-29 Beth Israel Deaconess Medical Center, Inc. Carbon Monoxide Improves Outcomes in Cell and Organ Transplants and Suppresses Apoptosis
NZ534912A (en) 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
SG148850A1 (en) 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
EP1499186A4 (en) 2002-04-15 2009-10-28 Beth Israel Hospital USE OF HEME-OXYGENASE-1 AND HEME DEGRADATION PRODUCTS
PL373002A1 (en) * 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
MXPA04010242A (es) * 2002-04-15 2005-06-08 Univ Pittsburgh Metodos para tratar enterocolitis necrotizante.
DK1505990T3 (da) * 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
EA200401622A1 (ru) * 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
HRP20041204A2 (en) * 2002-06-21 2005-06-30 University Of Pittsburgh Of The Commonwealth Systebeth Israel Deaconess Medical Center Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
BRPI0415752A (pt) * 2003-10-22 2006-12-19 Hutchinson Fred Cancer Res métodos, composições e dispositivos para indução de estase em células, tecidos, órgãos e organismos
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
EP1863503B1 (en) 2005-03-07 2019-05-22 Sangart, Inc. Composition for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
US7977042B2 (en) * 2005-07-27 2011-07-12 University Of North Carolina At Charlotte Composition and method for the restoration and preservation of transplant organs procured from DCD donors
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
WO2007073225A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
KR20090087900A (ko) 2006-11-07 2009-08-18 더 제너럴 하스피탈 코포레이션 혈관작용성 산소운반체에 의해 유도되는 혈관수축의 감소
EP2435121B1 (en) 2009-05-27 2017-04-05 INO Therapeutics LLC Device for engaging an indexed valve and pressurized canister assembly with a collar
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
CN103491783A (zh) 2011-01-14 2014-01-01 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
CA2830420A1 (en) 2011-03-16 2012-09-20 Mayo Foundation For Medical Education And Research Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
JP2014520113A (ja) * 2011-06-10 2014-08-21 ゲノ エルエルシー 一酸化窒素（ｎｏ）の加圧容器
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
EP2741821A4 (en) 2011-08-09 2015-10-07 Beth Israel Hospital METHOD FOR TREATING DNA DAMAGE
ES2981406T3 (es) 2013-03-15 2024-10-08 Mallinckrodt Pharmaceuticals Ireland Ltd Administración y monitorización de óxido nítrico en fluidos ex vivo
US9629358B2 (en) 2013-03-15 2017-04-25 Mallinckrodt Hospital Products IP Limited Administration and monitoring of nitric oxide in ex vivo fluids
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
EP3334484B1 (en) 2015-08-12 2024-12-25 The General Hospital Corporation Compositions that promote hypoxia or the hypoxia response for the treatment and prevention of mitochondrial dysfunction
CN105288599A (zh) * 2015-10-22 2016-02-03 徐州医学院 血红素氧化酶-2在制备抑制器官移植免疫排斥制剂中的应用
AU2018322317B2 (en) 2017-08-25 2023-11-23 Mallinckrodt Pharmaceuticals Ireland Limited Methods to improve organ viability
EP3524290A1 (en) 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Method and system for monitoring carbon monoxide (co) administration to ex-vivo fluids
CN116076484A (zh) * 2022-11-30 2023-05-09 武汉大学 一种修复肾脏损伤的低温携氧机械灌注液及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
CN85202057U (zh) * 1985-05-31 1986-09-10 南京低压阀门厂 电热丝预热凹槽式燃油系统
US5449665A (en) 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
DE3928144A1 (de) * 1989-08-25 1991-02-28 Hoechst Ag Zyklische pyridin-2,4- und -2,5-dicarbonsaeurediamide, verfahren zu deren herstellung sowie deren verwendung
US5180366A (en) 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5293875A (en) 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
WO1994018954A1 (en) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
AU6523194A (en) * 1993-03-26 1994-10-24 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5763431A (en) 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
DK0835115T3 (da) 1995-06-30 2004-08-02 Zymogenetics Inc 4-(2-(N-2-carboxamidoindo)aminoethyl)-benzensulfonamider eller -sulfonylurinstoffer som PDGF-antagonister
ES2267141T3 (es) 1996-04-05 2007-03-01 The General Hospital Corporation Tratamiento de una hemoglobinopatia.
US6069132A (en) 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
CN1191836C (zh) 1996-08-27 2005-03-09 梅塞尔集团有限公司 氢气作为药物活性成分在制备药物产品中的用途
US6316403B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
JP2001501612A (ja) * 1996-09-27 2001-02-06 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 虚血性疾患を治療する方法及び発作後の症状を改善する方法
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US5869538A (en) * 1996-11-26 1999-02-09 Research Foundation Of State University Of New York Method for enhancing transport of gases to tissues
FR2757259B1 (fr) * 1996-12-18 1999-03-05 Valeo Thermique Moteur Sa Ailette metallique perfectionnee pour echangeur de chaleur, notamment pour vehicule automobile
US5912019A (en) * 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury
KR20060036124A (ko) 1998-03-16 2006-04-27 셀진 코포레이션 염증성 사이토카인 억제제용2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그제조방법 및 그 용도
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6558825B1 (en) * 2000-05-12 2003-05-06 Reveo, Inc. Fuel containment and recycling system
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
US20040197271A1 (en) 2001-03-20 2004-10-07 Kunka Robert Leonard Inhalation drug combinations
EP1381354A2 (en) 2001-03-30 2004-01-21 Sangstat Medical Corporation Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (en) 2001-05-25 2005-06-15 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
EP2033514A3 (en) * 2001-06-21 2009-04-29 Beth Israel Deaconess Medical Center, Inc. Carbon Monoxide Improves Outcomes in Cell and Organ Transplants and Suppresses Apoptosis
NZ534912A (en) 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
SG148850A1 (en) * 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
EP1499186A4 (en) * 2002-04-15 2009-10-28 Beth Israel Hospital USE OF HEME-OXYGENASE-1 AND HEME DEGRADATION PRODUCTS
MXPA04010242A (es) * 2002-04-15 2005-06-08 Univ Pittsburgh Metodos para tratar enterocolitis necrotizante.
PL373002A1 (en) * 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
DK1505990T3 (da) * 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
EA200401622A1 (ru) * 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
HRP20041204A2 (en) * 2002-06-21 2005-06-30 University Of Pittsburgh Of The Commonwealth Systebeth Israel Deaconess Medical Center Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
NZ562962A (en) 2009-08-28
DK1404811T3 (da) 2009-03-02
EP1404811A4 (en) 2006-08-09
CN100502650C (zh) 2009-06-24
SI1404811T1 (sl) 2009-04-30
NO20035637L (no) 2004-02-17
WO2003000114A2 (en) 2003-01-03
DE60229848D1 (de) 2008-12-24
CA2451266A1 (en) 2003-01-03
NO20035637D0 (no) 2003-12-17
BG108492A (bg) 2005-02-28
ES2316583T3 (es) 2009-04-16
CY1108798T1 (el) 2014-04-09
HK1067380A1 (en) 2005-04-08
EP1404811B1 (en) 2008-11-12
CZ20033448A3 (cs) 2004-05-12
HUP0400371A2 (hu) 2004-08-30
SG147305A1 (en) 2008-11-28
WO2003000114A3 (en) 2003-04-10
WO2003000114A9 (en) 2004-05-21
CN1545548A (zh) 2004-11-10
US20030039638A1 (en) 2003-02-27
MXPA03012031A (es) 2005-07-01
EP1404811A2 (en) 2004-04-07
PT1404811E (pt) 2009-01-22
US7238469B2 (en) 2007-07-03
JP2005500875A (ja) 2005-01-13
AU2008221551A1 (en) 2008-10-09
KR20040032115A (ko) 2004-04-14
EP2033514A2 (en) 2009-03-11
JP4521183B2 (ja) 2010-08-11
PL367544A1 (en) 2005-02-21
BR0210599A (pt) 2004-07-20
AU2002318377B2 (en) 2008-06-19
ATE413883T1 (de) 2008-11-15
EP2033514A3 (en) 2009-04-29
US20070202083A1 (en) 2007-08-30
SK15942003A3 (sk) 2004-08-03

Similar Documents

Publication Publication Date Title
HUP0400371A3 (en) Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1424994A4 (en) PREPARATION OF A SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION
IL176932A0 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL183435A0 (en) Therapeutic formulations of keratinocyte growth factor
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
HUP0203138A3 (en) Carbon monoxide source for preparation of transition-metal-carbonyl-complexes
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL157231A0 (en) Parasiticidal compositions and methods of use
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
HUP0303055A3 (en) Polymorphs of zaleplon and methods for the preparation thereof and pharmaceutical compositions containing them
HUP0500103A3 (en) Tetracyclic compounds containing oxygen and/or sulfur atom, process for the preparation of some of them, their use and pharmaceutical compositions containing them
IL164470A (en) Pharmaceutical composition comprising arsenite for the treatment of solid malignancies
EP1617810A4 (en) PROCESS FOR THE PREPARATION AND USE OF 1ALPHA, 24 (S) -DIHYDROXYVITAMINE D2
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
DE10192157D2 (de) Lagerungshilfe zur tomographischen Funktionsuntersuchung der Lendenwirbelsäule
AU2003246614A8 (en) Novel use of lipopeptide preparations
HUP0400737A3 (en) Use of l-carnitine for preparation of compositions for stabilizing the proteins
AU2002239417A1 (en) Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: IKARIA HOLDINGS, INC., US

Free format text: FORMER OWNER(S): GOSE, JEANNE, US

Owner name: YALE UNIVERSITY, US

Free format text: FORMER OWNER(S): GOSE, JEANNE, US

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., US

Free format text: FORMER OWNER(S): GOSE, JEANNE, US

FD9A Lapse of provisional protection due to non-payment of fees